CJC-1295[Modified GRF (1-29); with DAC]
Compound snapshot
Class
Research peptide
FDA approved
No
Clinical development
Preclinical
Last reviewed
September 2026
Research areas
Growth hormone axis / Body composition / Recovery
Regulatory status
Research use only — not approved
Internet attention
Moderate
Registry query
CJC-1295
A synthetic analogue of growth hormone releasing hormone (GHRH). The 'with DAC' version binds albumin and lasts days rather than minutes.
Reality check — what we actually know
Supported by human evidence
- No adequately powered randomised human trials establish the outcomes this compound is marketed for.
Animal research only
- Sustained elevation of GH and IGF-1 in human pharmacology studies (an early trial reported multi-fold GH increases)
- Supports lean-mass retention during energy restriction in animal models
- Connective-tissue and bone turnover support via IGF-1
Mechanistically plausible
- Acts on the GHRH receptor to increase the amplitude of GH pulses. Frequently paired in the literature with a secretagogue like ipamorelin because the two act on different receptors.
Common internet claims
- Online discussion frequently presents CJC-1295 as a proven treatment rather than a research compound.
Not established
- Human efficacy for the outcomes commonly claimed
- Optimal route, quantity and duration in humans
- Long-term human safety
Evidence distribution
Each band is a live PubMed search for CJC-1295, filtered to that kind of study. Top is the strongest evidence; the base is reasoning, not proof. A band with no records means that kind of study has not been published for this compound yet.
Mechanism and reported findings
Acts on the GHRH receptor to increase the amplitude of GH pulses. Frequently paired in the literature with a secretagogue like ipamorelin because the two act on different receptors.
- Sustained elevation of GH and IGF-1 in human pharmacology studies (an early trial reported multi-fold GH increases)
- Supports lean-mass retention during energy restriction in animal models
- Connective-tissue and bone turnover support via IGF-1
- Longer dosing interval than short-acting GHRH analogues
Strength of the evidence: Human pharmacokinetic and pharmacodynamic data exist; development was halted and there is no approved indication. A trial death (unrelated cause reported) is often cited in the history of the compound.
Safety and known cautions
Continuous rather than pulsatile GH elevation is physiologically unnatural. Same tumour-signalling, oedema and glucose concerns as other GH-axis compounds. WADA-prohibited.
Evidence at a glance
No single score, on purpose. The line beside each bar shows how much reported outcomes vary between studies.
Development stage
- Discovery
- PreclinicalCurrent
- Phase 1
- Phase 2
- Phase 3
- Regulatory review
- Approved